Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients

Inclusion Criteria: * Clinical diagnosis of onychomycosis confirmed through positive KOH stain or positive mycologic culture findings. * Involvement of at minimum 20% of the target great toenail. Exclusion Criteria: * Diagnosis of a nondermatophyte fungus infection, diagnosis of proximal subungual onychomycosis, diagnosis of superficial white onychomycosis * Diagnosis of peripheral arterial disease or anatomic abnormalities of the target toenail * Inability to follow through with all requisite office visits * Routine use of a systemic corticosteroid, routine use of a systemic immunomodulator, or history of systemic antifungals within the prior five years. * Active interdigital tinea pedis refractory to topical antifungal treatments * Known hypersensitivity to efinaconazole * Use, within the month preceding screening, of: topical antifungal agents, topical anti-inflammatory agents to the toes * Any history of oral systemic antifungal with known activity against dermatophytes